Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial

Published:2023-08 Issue:10403 Volume:402 Page:720-730
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Frias Juan P,Deenadayalan Srikanth,Erichsen Lars,Knop Filip K,Lingvay Ildiko,Macura Stanislava,Mathieu Chantal,Pedersen Sue D,Davies Melanie

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Managing obesity in people with type 2 diabetes;Grant;Clin Med (Lond),2021

2. Standards of care in diabetes—2023;Diabetes Care,2023

3. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD;Cosentino;Eur Heart J,2020

4. Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD);Davies;Diabetologia,2022

5. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation;Lingvay;Lancet,2022

Cited by 80 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tratamiento farmacológico de la obesidad. Situación actual y nuevos tratamientos;Atención Primaria;2025-01

2. Future is Brighter: New Potential Paradigm-Shifting Medications and Regimens for Diabetes and Obesity;Current Diabetes Reviews;2024-10

3. Assessing the therapeutic and toxicological profile of novel GLP-1 receptor agonists for type 2 diabetes;Expert Opinion on Drug Metabolism & Toxicology;2024-09-13

4. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis;Indian Journal of Endocrinology and Metabolism;2024-09-04

5. Lead–in calorie restriction enhances the weight-lowering efficacy of incretin hormone-based pharmacotherapies in mice;Molecular Metabolism;2024-09